A950200 Stock Overview
Engages in the provision of multi-omics solutions for clinical and research purposes. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Psomagen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,430.00 |
| 52 Week High | ₩6,700.00 |
| 52 Week Low | ₩3,800.00 |
| Beta | 0.11 |
| 11 Month Change | 6.75% |
| 3 Month Change | -3.80% |
| 1 Year Change | -15.78% |
| 33 Year Change | -53.56% |
| 5 Year Change | n/a |
| Change since IPO | -70.66% |
Recent News & Updates
Companies Like Psomagen (KOSDAQ:950200) Are In A Position To Invest In Growth
Aug 28
A Look At The Fair Value Of Psomagen, Inc. (KOSDAQ:950200)
Jul 05
Shareholder Returns
| A950200 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 10.5% | -4.2% | 1.9% |
| 1Y | -15.8% | 19.5% | -2.6% |
Return vs Industry: A950200 underperformed the KR Biotechs industry which returned 24.9% over the past year.
Return vs Market: A950200 underperformed the KR Market which returned -1.1% over the past year.
Price Volatility
| A950200 volatility | |
|---|---|
| A950200 Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A950200 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A950200's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 93 | n/a | www.psomagen.com |
Psomagen, Inc. engages in the provision of multi-omics solutions for clinical and research purposes. The company provides genomics, a study of gene sequence and expression; epigenomics, a study of epigenetic changes, such as chromatin assembly, histone modification, and DNA-protein interaction in a cell; metagenomics, a study of genetic material from microorganisms in heterogeneous samples; transcriptomics, a study of RNA and its expression through sequencing, offered to analyze the impact of gene expression on the biology of an organism; and proteomics, a study of all the expressed proteins in an organism (proteome). It also offers Bioinformatics, a software tool and pipeline that helps scientists in analyzing data, as well as provides clinical testing solutions.
Psomagen, Inc. Fundamentals Summary
| A950200 fundamental statistics | |
|---|---|
| Market cap | ₩85.22b |
| Earnings (TTM) | -₩6.15b |
| Revenue (TTM) | ₩34.07b |
2.5x
P/S Ratio-13.9x
P/E RatioIs A950200 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A950200 income statement (TTM) | |
|---|---|
| Revenue | ₩34.07b |
| Cost of Revenue | ₩26.96b |
| Gross Profit | ₩7.11b |
| Other Expenses | ₩13.26b |
| Earnings | -₩6.15b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -319.80 |
| Gross Margin | 20.87% |
| Net Profit Margin | -18.06% |
| Debt/Equity Ratio | 1.7% |
How did A950200 perform over the long term?
See historical performance and comparison